This website uses cookies primarily for visitor analytics. Certain pages will ask you to fill in contact details to receive additional information. On these pages you have the option of having the site log your details for future visits. Indicating you want the site to remember your details will place a cookie on your device. To view our full cookie policy, please click here. You can also view it at any time by going to our Contact Us page.

GSH to maintain 14th location for AstraZeneca

07 April 2009

AstraZeneca has awarded a three-year FM contract to GSH Group to provide building and maintenance services at its Charnwood site in Loughborough including M&E engineering, air conditioning, building fabric maintenance and environmental services.

AstraZeneca selected GSH Group following a competitive tender process, which saw GSH Group demonstrate its wide range of facilities management capabilities together with a culture of delivering cost and service delivery benefits through innovation and partnering. The Charnwood site is focused on finding new medicines for respiratory and inflammatory diseases.

This latest deal brings the number of AstraZeneca locations maintained by GSH Group to fourteen including the company’s London Global Headquarters, UKMC Sales and Marketing facility and National Distribution Centre. GSH Group has worked closely with AstraZeneca to maximise service delivery, whilst achieving significant initial and progressive cost savings across the existing portfolio of sites.

David Curtis, Procurement Manager at AstraZeneca commented: “GSH Group has a proven track record of providing high-quality facilities management solutions, and this latest contract award is recognition of the successful and long-standing relationship between the two companies. GSH Group possesses the ability to provide a cost-effective service, with a partnership approach that is both flexible and innovative.”

Jamie Reynolds, Co-Chief Executive at GSH Group said: “GSH Group has the expertise to ensure the consistency of all key service delivery requirements and maintain the site continuity, enabling AstraZeneca to focus on their core business activities and remain at the forefront of medical research. This contract is the culmination of many years work and confirms the strength and commitment of our team.”

Contact Details and Archive...

Print this page | E-mail this page